Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News -
It was an unintentionally revealing discussion about the history and reality of agreements
June 9, 2026 - - Latest News -
R&D tax shake up risks sending Australia’s biotech talent and jobs overseas
June 9, 2026 - - Latest News -
Rare Cancers Australia co-founder Kate Vines recognised in King's Birthday Honours
June 8, 2026 - - Latest News -
Omico is evolving tumour genomics into hard evidence for precision oncology
June 8, 2026 - - Latest News -
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News

